It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
Image source: Getty Images
CSL Ltd (ASX: CSL)
According to a note out of Citi, its analysts have retained their buy rating and $345.00 price target on this biotechnology company's shares. Citi highlights that the company's shares have been under pressure this month amid concerns over what impact Donald Trump's US election win could have on its vaccines business and the pharmaceutical industry. However, the broker suspects that CSL could get off lightly from any potential legislation on drug pricing because its gross margin is lower than the pharmaceutical industry average and many of its products are life-saving and have no substitutes. As a result, Citi believes that recent weakness has created a buying opportunity for investors. The CSL share price ended the week at $276.47.
IGO Ltd (ASX: IGO)
A note out of Goldman Sachs reveals that its analysts have retained their buy rating and $6.20 price target on this lithium miner's shares. This follows the release of its latest lithium price update. Unfortunately, nothing has changed in respect to forecasts and Goldman continues to believe that weaker prices are here to stay for at least the next three years. But it doesn't think this should stop you from buying IGO's shares. That's because its low production costs means it should still be offering positive near term free cash flow yields. In addition, the broker highlights IGO's discount to peers and the Greenbushes expansion as reasons to be positive. It believes the latter expansion remains one of the most economically compelling brownfield lithium projects around. The IGO share price was fetching $4.95 at Friday's close.
TechnologyOne Ltd (ASX: TNE)
Analysts at UBS have retained their buy rating on this enterprise software provider's shares with an improved price target of $33.80. According to the note, UBS was impressed with TechnologyOne's FY 2024 results last week. The broker notes that the company's profit before tax was well ahead of expectations and driven by further strong recurring revenue growth. Looking ahead, UBS is confident that more of the same is coming. So much so, it sees scope for TechnologyOne's profit before tax to grow at approximately 20% per annum for the next five years. In light of this, the broker believes that the high-flying tech stock deserves to trade with a premium valuation. The TechnologyOne share price ended the week at $30.49.
